Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that interim results
from the COSMOS study (Combination Of SiMeprevir and sOfosbuvir in HCV genotype
1 infected patientS) have been presented at the 20th Conference on Retroviruses
and Opportunistic Infections (CROI) on March 6 in Atlanta, Georgia, USA.
These COSMOS interim results are from the first cohort of a phase IIa study of
the investigational protease inhibitor simeprevir (TMC435) administered once
daily with Gilead’s investigational nucleotide inhibitor sofosbuvir (GS-7977)
with and without ribavirin (RBV) for 12 and 24 weeks in genotype 1 prior null
-responder hepatitis C patients with mild to moderate fibrosis (METAVIR F0-2).
Simeprevir is jointly developed by Medivir AB and Janssen R&D Ireland, an
affiliate of the Janssen Pharmaceutical Companies.